Articles On Memphasys (ASX:MEM)

This content is created by Smallcaps Authors. [Author : Imelda Cotton] In vitro results from study findings on the Felix system developed by reproductive biotechnology company Memphasys (ASX: MEM) have demonstrated it can outperform conve...

Creso looks to potentially spin out psychedelic subsidiary  Two studies show Memphasys’ Felix reproductive tech outperforms WOA’s Dirty Clean Food brand nabs WHSmith retail deal   Yesterday the big news in the health sector was the Thera...

ShareCafeASX up 0.12% at noon as investors await this afternoon’s RBA meeting by Peter Milios   Investors are cautious as they await the outcome of the Reserve Bank’s meeting and examine local earnings updates. As a result, the Australian s...

ShareCafeStocks of the Hour: C29, EVR, MEM                    C29 Metals (ASX:C29) advises that drilling at their Pocitos 7 project in Argentina has concluded at 420 metres, with a packer test intercepting a deep aquifer from 370-400...

07 Feb 2023 - A snapshot of the stocks on the move featuring C29 Metals (ASX:C29), EV Resources (ASX:EVR) and Memphasys (ASX:MEM).

The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry   The US FDA announced last week that:...

Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past...

The ASX 200 rose a tidy 1.29% today with all sectors in the green ABS releases Aussie migrant data employment outcomes for the first time  ACCC gives the thumbs down to Telstra and TPG’s merger plans   The ASX 200 gained 1.29% today and...

The ASX 200 was in the red again, down 0.21% today 9 out 11 sectors finished lower led by Real Estate, with Energy and Materials gaining Stockmarkets head into the festive period in a downbeat mood, Oanda says   The ASX 200 was down 0.21%...

ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and...

Wall St surged after a media report signalled the Fed might be slowing down its rate hikes from December Snap Inc plunged 28% on a bad quarter Tuesday’s Federal Budget will be the market’s focus this week Local shares are set to open shar...

Blood clot programs have taken the spotlight recently as new discoveries made Two ASX health stocks are in the blood clot space Top performing ASX healthcare stocks in the past month Blood clots were top of biotech news this week after re...

Small cap index up 1.1%, stronger than benchmark, but both do good, run hard.   Wall Street snaps 3-day losing streak, China could be back in stimmy mode Uranium’s gone insanium   The ASX 200 is up 0.7% and the Emerging Companies (XEC) in...

Small caps and benchmark down over 1% All sectors retreat on ill-winds blowing in from the states Tinkler is back   The ASX 200 has started a new week with its worst session since early July. While that can be pinned on a shift in US sent...

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Small caps creep up 0.018%, ASX 200 stays flat Energy sector jumps with Karoon Energy and Terracom both up 7%+ The RBA is aiming for a soft landing for the economy   The ASX 200 was unchanged today with only six out of eleven sectors hig...

The ASX200 is down 0.24% dragged down by the tech sector Eight out of eleven sectors were lower, with Tech leading the losers CBA says the unemployment rate is at its lowest in 48 years   Despite creeping up earlier in the week the ASX 20...

The ASX200 is up 0.31% with the ABS reporting strong wage growth Seven out of eleven sectors were higher, with consumer staples leading the charge Real wages of Australians are going backwards due to the rising cost of living   The ASX 2...

Reproduction biotechnology and bio-separations company Memphasys (MEM) launches a $3.36 million capital raising The raise will comprise a $1.6 million placement and a $1.76 million non-renounceable entitlement offer The placement funds wil...

ASX 200 is up 0.2% and the XEC is down -0.2% Tension stateside ahead of FOMC decision, EU markets to start flat CPI at 6.1% is better than feared but enough to move the RBA next Tuesday And a crack team of small caps broke out of the ordin...

Reproduction biotechnology and bio-separations company Memphasys (MEM) enters a mid-week trading halt ahead of a capital raising The company will remain in the trading halt until Friday, July 29, or when further details are released to the...

While the bigger end of the towns tides out pre-earnings blackouts, small caps are making the most of ASX’s green days and fronting investors with cash calls. 

US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F...

A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m...

Sydney biotechnology company Memphasys has passed another milestone on the route to commercialising its unique reproductive technology device, enrolling and treating the first couple in its new clinical study.

Memphasys (MEM) has enrolled and treated the first couple under a clinical study trialling the safety and performance of its Felix device The study is being conducted with reproductive and fertility services company Monash IVF Group and w...

Avita Medical makes spray on skin for burns and soft tissue injuries HITIQ’s concussion tech is popular for athletes and sports teams PainChek’s smartphone app can tell if babies or older Aussies are in pain There’s a plethora of biotech...

Australian reproductive biotechnology company Memphasys is taking advantage of the worldwide easing of travel rules to turbocharge its trademarked Felix System into global IVF markets.

Neurotech says its cannabis strain NTI164 demonstrates strong results when combined with Diclofenac Memphasys prepares for a pre-submission meeting with the US FDA for its sperm separation tech, the Felix System Neurotech reports positive...

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Emerging markets index ends flat ASX200 0.5 higher Chinese economy hit by COVID-lockdowns   Anaemic data out of China has taken the fun out of Monday here in Sydney. April retail sales fell more than 11% year on year, almost twice what wa...

Emerging markets index ends flat ASX200 0.5 higher Chinese economy hit by COVID-lockdowns   Anaemic data out of China has taken the fun out of Monday here in Sydney. April retail sales fell more than 11% year on year, almost twice what wa...

The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week  Dr Anthony Faucci, America’s top infectious disea...

The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite  A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot...

It’s been an emotional ride for fans of the ASX200 (XJO) which, alongside the Emerging Companies (XEC) index, (down 0.6%) gave up its early gains in a topsy-turvy Monday session. Just after the close, the XJO was weepingly flat – well, up 0...

Biotech sector has had a tough time recently But there are signs of things improving this year A look at biotech movers on the ASX in the past fortnight Biotech stocks entered a bear phase in the middle of 2021, and things haven’t improve...

The ASX 200 index has closed 1% higher on Monday, while the ASX Emerging Companies (XEC) index shed earlier gains to finish down 0.1%. Disappointing, really. It shoulda been a day for the little guys. Asia was mixed. Although not the Hong K...

Trailblazing biotech Memphasys has achieved a crucial step in the rollout of its IVF sperm separation technology after winning a draft ISO for its quality management system for manufacturing medical devices.

Telehealth was already a growing space even before the pandemic, but COVID had launched it into the mainstream. At the height of the pandemic in 2020, data from Research and Markets showed that 76% of hospitals in the US were using teleheal...

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

The ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial turn in the courts this week. The healthcare giant is currently staring down 38,000 claims that its talc products (including the famous baby...

The price action of ASX biotech shares was nothing short of a mixed bag in 2021. Several of the majors underperformed the benchmark S&P/ASX 200 Pharmaceuticals & Biotechnology index (AXPBJD), whereas many small-cap names came thro...

At the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, beating the ASX200 benchmark index which was up 2.8% for the period. Here’s a table showing how ASX-listed healthcare stocks have been perform...

It’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. CODE COMPANY PRICE 1 WEEK RETURN %...

The life sciences sector has emerged into the spotlight ever since the pandemic began. In the US, the share prices of major vaccine-producing companies have surged astronomically as COVID-19  ravaged the world. Nasdaq-listed BioNTech, which...

Memphasys has landed the first sale of its revolutionary trademarked Felix bio-separation technology placed by a women’s centre in Coimbatore, India which will be the first to use the system for clinical IVF.

Memphasys is rapidly hurtling towards commercialising with its “Felix” IVF reproductive technology. Clinical trials are set to commence at four Monash IVF Australian clinics soon.

Investing in ASX biotech shares was an underwhelming affair in November. As a basket, the sector lagged key benchmarks, and many names saw substantial declines in value over the month. Renewed fears from the Omicron COVID-19 variant saw in...

It’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 losing it and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Name Price % Six Mont...